We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

11 hedge funds and large institutions have $413K invested in Cellectar Biosciences in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

9.31% less ownership

Funds ownership: 17.08% → 7.77% (-9.3%)

15% less funds holding

Funds holding: 13 → 11 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

80% less capital inflows, than outflows

Capital inflows: $150K | Capital outflows: $762K

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$103K
2
Citadel Advisors
Citadel Advisors
Florida
+$34.9K
3
UBS Group
UBS Group
Switzerland
+$7.83K
4
Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services
Florida
+$4.27K

Top Sellers

Rank Fund Capital Flow
1
Wexford Capital
Wexford Capital
Florida
-$750K
2
Vigilant Capital Management
Vigilant Capital Management
Maine
-$6K
3
Renaissance Technologies
Renaissance Technologies
New York
-$3.56K
4
Iron Gate Global Advisors
Iron Gate Global Advisors
Utah
-$2K
5
Bank of America
Bank of America
North Carolina
-$712

CLRB Hedge Fund Activity: Q4 2018 in Review

11 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2018, worth a combined $413K — down 70% from $1.37M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CLRB and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, adding an estimated $103K. The largest seller was Wexford Capital, exiting entirely with an estimated $750K sold.

  • 11 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2018, down from 13 in Q3 2018.
  • Funds reported $413K of Cellectar Biosciences stock for Q4 2018, down 70% quarter-over-quarter.
  • 2 funds opened new Cellectar Biosciences positions in Q4 2018 and 4 closed out, a net change of -2 holders.
  • The largest Cellectar Biosciences buyer in Q4 2018 was Morgan Stanley, an estimated $103K added.
  • The largest Cellectar Biosciences seller in Q4 2018 was Wexford Capital, an estimated $750K sold.

Based on aggregated 13F filings for Q4 2018.